Key result
Initial combination therapy with valsartan/amlodipine reduced the mean time to achieve blood pressure goal compared to conventional monotherapy.
Why the study?
Does initial combination therapy with valsartan/amlodipine reduce the time to achieve blood pressure goals compared to sequential monotherapy in hypertensive patients with metabolic syndrome?
RCT (n=308)
Does initial combination therapy with valsartan/amlodipine reduce the time to achieve blood pressure goals compared to sequential monotherapy in hypertensive patients with metabolic syndrome?
Initial combination therapy with valsartan and amlodipine achieves blood pressure targets more rapidly than a sequential monotherapy approach in hypertensive patients with metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Supports initial combination for faster BP control in metabolic syndrome hypertension; extends RCT evidence for early dual therapy.
The time to achieve a blood pressure (BP) goal < or =130/85 mmHg with a combination versus a conventional monotherapy approach was evaluated in 308 hypertensive patients with metabolic syndrome. They were randomized to valsartan (V) 8 mg/amlodipine (A) 5 mg combination or to V 160 mg monotherapy for 12 weeks and every 2 weeks, there was a titration in nonresponder patients: in the combination group V/A was progressively increased to V 160/A 5 mg; V160/A 7.5 mg; V160/A 10 mg; V 240/A 10 mg, and V 320/A 10 mg. In the monotherapy group, the regimen was progressively modified as following: V 240 mg; V 320 mg; V 320/A 5 mg; V 320/A 7.5 mg, and V 320/A 10 mg. The mean time to achieve the BP goal was shorter in patients randomized to combination therapy compared to those randomized to conventional monotherapy (4.7 +/- 2.7 weeks vs. 7.1 +/- 3.9 weeks, respectively, p < 0.001). The percentage of patients who achieved target BP in the combination approach group statistically exceeded that of the monotherapy treated one already after 2 weeks of treatment (30.5 vs. 14.9%, p < 0.01) and again after 4, 6, 8, and 10 weeks of treatment. Only at 12 weeks the percentage of normalized patients was similar in the two treatment groups (78.8% vs. 75.3%, ns). These results suggest that initial therapy with a V/A combination approach may be more quickly effective than a conventional sequential monotherapy approach in achieving target BP in hypertensive patients with metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Fogari et al. (2010) conducted an RCT in Hypertension with metabolic syndrome (n=308). Valsartan/amlodipine combination therapy vs. Conventional monotherapy (valsartan 160 mg, titrated up to 320/10 mg) was evaluated on Mean time to achieve blood pressure goal ≤130/85 mmHg (in weeks) (p=<0.001). Initial combination therapy with valsartan/amlodipine reduced the mean time to achieve blood pressure goal compared to conventional monotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: